

DERMA SCIENCES, INC.
Form 8-K
April 02, 2007

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): March 30, 2007

Derma Sciences, Inc.

(Exact name of registrant as specified in its charter)

Pennsylvania
(State or other jurisdiction
of incorporation)

1-31070
(Commission
File Number)

23-2328753
(IRS employer
identification number)

214 Carnegie Center, Suite 100
Princeton, NJ 08540
(609) 514-4744

(Address including zip code and telephone
number, of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

Derma Sciences, Inc. (the Company) will issue a press release on Monday, April 2, 2007 at 7:00 a.m. announcing its operating results for the three months and year ended December 31, 2006 and 2005. The release will also contain analysis and comments of Edward J. Quilty and John E. Yetter, the Company's Chief Executive Officer and Chief Financial Officer, respectively, together with an announcement of the Company's public conference call and webcast to be held Monday, April 2, 2007 at 11:00 a.m.

A copy of the subject press release is attached hereto as Exhibit 99.01.

Item 9.01. Financial Statements and Exhibits

(c) Exhibits

99.01 Press Release Announcing Financial Results

Edgar Filing: DERMA SCIENCES, INC. - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DERMA SCIENCES, INC.

By: /s/ John E. Yetter
John E. Yetter, CPA
Vice President and Chief Financial Officer

Date: March 30, 2007